A Novel Treatment Schedule for Rapid Completion of Surgery and Radiation in Early-Stage Breast Cancer
Data support the use of accelerated partial-breast irradiation (APBI) for early-stage breast cancer. We initiated a prospective protocol for intraoperative APBI catheter placement using a multi-lumen strut-based device. We hypothesized that with intraoperative pathology assessment of margins and sentinel nodes, all locoregional treatment (surgery and APBI) could be completed within 10 days with acceptable complication rates and cosmesis.
Eligible patients included women age 50 years or older with clinical T1 estrogen receptor positive (ER+) sentinel lymph node (SLN)-negative invasive ductal cancer or pure ductal carcinoma in situ. Patients were prospectively registered. Cosmesis was assessed using photographs graded independently by three investigators for patients with photos taken 6 months or longer after treatment.
From October 2012 to August 2015, we enrolled 123 patients; 110 (90 %) underwent intraoperative catheter placement, whereas 13 did not due to intraoperative pathology findings. 109 APBI patients (99 %) completed their prescribed radiotherapy within 5 days, and all their locoregional therapy within 9 days, whereas one patient with a delayed positive SLN received only boost radiotherapy via catheter followed by conventional whole breast radiation. The 30-day complication rate was 6 %. In 81 patients with at least one-year followup, complications occurred in 14 (17 %) (including infection in five patients and symptomatic seroma in five patients) and correlated with device size (p = 0.05) but not with tumor size or location. The local recurrence rate was 1.8 % (two patients). Scored cosmesis was excellent or good in 88 % and fair in 12 % of patients.
A protocol for intraoperative strut-based APBI catheter placement using careful patient selection and intraoperative pathology assessment can deliver efficient, effective treatment for early breast cancer.
KeywordsIpsilateral Breast Tumor Recurrence Locoregional Therapy Interstitial Brachytherapy Ipsilateral Breast Tumor Recurrence Rate Interstitial Multicatheter Brachytherapy
Conflict of Interest
There are no conflicts of interest.
- 4.Surgeons ACo. Commission on Cancer Quality of Care Measures. Available at https://www.facsorg/quality-programs/cancer/ncdb/qualitymeasures. Accessed 1 Mar 2016.
- 7.Pan IW, Smith BD, Shih YC. Factors contributing to underuse of radiation among younger women with breast cancer. J Natl Cancer Inst. 2014;106:djt340.Google Scholar
- 10.Strnad V, Ott OJ, Hildebrandt G, et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet. 2016;387:229–38.CrossRefPubMedGoogle Scholar
- 17.Smith GL, Xu Y, Buchholz TA, Giordano SH, Jiang J, Shih YC, etal. Association between treatment with brachytherapy vs whole-breast irradiation and subsequent mastectomy, complications, and survival among older women with invasive breast cancer. JAMA. 2012;307:1827–37.PubMedPubMedCentralGoogle Scholar
- 23.Surgeons ASoB. Consensus Statement for Accelerated Partial Breast Irradiation. Available at http://www.breastsurgeonsorg/statements/PDF_Statements/APBIpdf. Accessed 1 Mar 2016.
- 24.Polgar C, Van Limbergen E, Potter R, et al. Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: recommendations of the Groupe Europeen de Curietherapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009). Radiother Oncol. 2010;94:264–73.CrossRefPubMedGoogle Scholar
- 28.RTOG 0413 Protocol Information NSABP B-39: A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer. Available at https://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0413. Accessed 1 Mar 2016.
- 32.Wobb JL, Shah C, Chen PY, Wallace M, Ye H, Jawad MS, et al. Brachytherapy-based acccelerated partial breast irradiation provides equivalent 10-year outcomes to whole breast irradiation: a matched-pair analysis. Am J Clin Oncol. doi: 10.1097/COC.0000000000000082.
- 33.Beitsch PD, Wilkinson JB, Vicini FA, et al. Tumor bed control with balloon-based accelerated partial breast irradiation: incidence of true recurrences versus elsewhere failures in the American Society of Breast Surgery MammoSite((R)) Registry Trial. Ann Surg Oncol. 2012;19:3165–70.CrossRefPubMedGoogle Scholar
- 41.Vicini F, Beitsch PD, Quiet CA, et al. Three-year analysis of treatment efficacy, cosmesis, and toxicity by the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial in patients treated with accelerated partial breast irradiation (APBI). Cancer. 2008;112:758–66.CrossRefPubMedGoogle Scholar
- 42.Yashar CM, Scanderbeg D, Kuske R, Wallace A, Zannis V, Blair S, et al. Initial clinical experience with the Strut-Adjusted Volume Implant (SAVI) breast brachytherapy device for accelerated partial-breast irradiation (APBI): first 100 patients with more than 1 year of follow-up. Int J Radiat Oncol Biol Phys. 2011;80:765–70.CrossRefPubMedGoogle Scholar